With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

Total revenues increased 10% year over year to $3.79 billion, fueled by increased collaboration revenues from Sanofi for Dupixent, higher Eylea HD and Libtayo sales. Revenues marginally beat the ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with ...